P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

Authors :: E. Ellingsen
Vilde Drageset Haakensen
Saima Jamil Farooqi
Susana Cedres
Anna K. Nowak
Åslaug Helland
Tine McCulloch
O. Grundberg
Maria Moksnes Bjaanæs
Source :: Journal of Thoracic Oncology. 16:S380
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Ipilimumab
medicine.disease
Vaccination
Internal medicine
medicine
In patient
Mesothelioma
Line (text file)
Nivolumab
business
medicine.drug

Full Text Access

Tools